RECOVER-ENERGIZE 플랫폼 프로토콜_부록 B(구조적 페이싱(PEM))
RECOVER-ENERGIZE: SARS-CoV-2 감염(PASC) 급성 후유증의 운동 불내성에 대한 중재를 평가하기 위한 플랫폼 프로토콜
This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes.
This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating interventions to address and improve exercise intolerance and post-exertional malaise (PEM) as manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC).
The focus of this protocol is to assess interventions that can improve exercise capacity, daily activities tolerance, and quality of life in patients with PASC.
연구 개요
상세 설명
Study interventions will be added to the platform protocol as appendices. Each appendix will leverage all elements of the platform protocol, with additional elements described in the individual appendix. Study intervention appendices may be added or removed according to adaptive design and/or emerging evidence.
The platform protocol enrolls participants who meet study eligibility criteria. After completing initial screening assessments, eligible participants are assigned to one of the study intervention appendices that are actively enrolling. Participants must meet certain criteria within a specific appendix in order to be included in that appendix. Once assigned to an appendix, eligible participants are randomized to either the study intervention group or a control group.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
North Carolina
-
Durham, North Carolina, 미국, 27710
- All sites listed under NCT06404047
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
• See NCT06404047 for RECOVER-ENERGIZE: Platform Protocol level inclusion and exclusion criteria which applies to this appendix
Additional Appendix B (Structured Pacing (PEM)) Level Inclusion Criteria:
- Participant identifies new PEM following a SARS-CoV-2 infection that has persisted for at least 12 weeks and is still present at the time of consent
- Score of 2 or greater for both frequency and severity for any of the first 5 questions on the Screening mDSQ-PEM AND Answer of YES to either item 7 or 8 on Screening mDSQ-PEM, and response of >14 h in item 9.
or Score of 3 or greater on any severity question(regardless) and answer of YES to either item 7 or 8 on the Screening mDSQ-PEM, and response of >14h in item 9.
Additional Appendix B (Structured Pacing (PEM)) Level Exclusion Criteria:
- Inability to attend in-person screening visit or participate in weekly visits (in-person [≥ 1] and remote)
- Participant was previously enrolled in Appendix A of this protocol and has NOT completed the full study follow-up period of Appendix A
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Structured Pacing (PEM)
Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications. |
Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications. |
|
다른: Usual Care
Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication. |
Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in Frequency of PEM Symptoms, as Measured by the Modified DePaul Symptom - Post-Exertional Malaise Questionnaire (mDSQ-PEM)
기간: Baseline, week 12 (End Of Intervention, EOI)
|
Symptom frequency is rated on a 5-point Likert scale: 0 = none of the time, 1 = a little of the time, 2 = about half the time, 3 = most of the time, and 4 = all of the time. |
Baseline, week 12 (End Of Intervention, EOI)
|
|
Change in Severity of PEM Symptoms, as Measured by the Modified DePaul Symptom - Post-Exertional Malaise Questionnaire (mDSQ-PEM)
기간: Baseline, week 12 (EOI)
|
Symptom severity is rated on a 5-point Likert scale: 0 = symptom not present, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe. |
Baseline, week 12 (EOI)
|
|
Change in Duration of PEM Symptoms, as Measured by the Modified DePaul Symptom - Post-Exertional Malaise Questionnaire (mDSQ-PEM)
기간: Baseline, week 12 (EOI)
|
Ordinal categorical response: <=1 hour, 2-3 hours, 4-10 hours, 11-13 hours, 14-23 hours, >=24 hours. Reported as the number of participants who provided each response. |
Baseline, week 12 (EOI)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in PASC Symptoms, as Measured by the PROMIS-Cog Questionnaire
기간: Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
The PROMIS Short Form v.2.0 - Cognitive Function 8a (PROMIS-Cog) is the PROMIS Short Form to assess cognitive function and is a self-report, 8-item questionnaire targeting cognitive function in the past seven days. T-Scores in a healthy reference population have mean=50 and standard deviation = 10, with higher scores indicating higher functioning. |
Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
|
Change in Quality of Life, as Measured by the PROMIS-29+2
기간: Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
The PROMIS-29+2 is used to calculate a preference score (PROPr) by the addition of two Cognitive Function Ability items. Preference-based scores provide an overall summary of health-related quality of life on a common metric. Preference-based scores summarize multiple domains on a metric ranging from 0 (as bad as dead) to 1 (perfect or ideal health). |
Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
|
Change in Quality of Life, as Measured by the EQ-5D 5L
기간: Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
The EQ-5D is a standardized measure of health status. Mobility was measured on a scale from 1 (no problems in walking) to 5 (unable to walk). |
Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
|
Change in Step Count (Physical Activity) as Measured by Actigraphy
기간: Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
Actigraphy will be measured by Fitbit. Participant steps were considered valid from days where they wore the Fitbit at least 10 waking hours. Average steps were calculated from subjects with at least 5 consecutive days of valid data within a week window of their expected visit dates. |
Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
|
Change in Physical Activity, as Measured by the PROMIS SF-Physical Function (PROMIS-PF)
기간: Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
The PROMIS Short Form v2.0 - Physical Function 8b (PROMIS-PF) consists of 8 items. The PROMIS Physical Function instruments measure self-reported capability rather than actual performance of physical activities. T-Scores in a healthy reference population have mean = 50 and standard deviation = 10, with higher scores indicating higher functioning. |
Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
|
Change in Orthostatic Hypotension, as Measured by the Modified Orthostatic Hypotension Questionnaire (mOHQ)
기간: Screening, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
The Orthostatic Hypotension Questionnaire (OHQ) is a measure of orthostatic intolerance. The modified OHQ (mOHQ) measure used in this study includes a total of ten items related to daily activities and symptoms. The OHQ composite score ranges from 0 (no burden) to 10 (maximal burden). Higher scores are worse. The OHQ composite score includes 6 symptom items (OISA) and 4 daily activity items (OIDAS). |
Screening, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in PASC Symptoms, as Measured by the PASC Symptom Questionnaire
기간: Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
The PASC Symptom Questionnaire is a 33-question survey for self-reporting multiple PASC-related symptoms across multiple systems. |
Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 의자: Gary M Felker, MD, Duke Clinical Research Institute
- 연구 의자: Barry Make, MD, National Jewish Health
- 연구 의자: Lucinda Bateman, MD, Bateman Horne Center
- 연구 의자: Janna Friedly, MD, MPH, University of Washington
간행물 및 유용한 링크
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- Pro00112409_B
- OT2HL156812 (미국 NIH 보조금/계약)
- NHLBI Grant to RTI (기타 보조금/기금 번호: RTI subcontracting with DCRI)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The summary of the results will be shared on the study website: https://recovercovid.org/
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .